Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Guo, L. Su, Y. Li, N. Guo, C. Liu (Beijing, China). The combined therapy of HGF and G-CSF for pulmonary hypertension in rats. Eur Respir J 2012; 40: Suppl. 56, 3178

Member's Comments

No comment yet.

Related content which might interest you: Hypoxia-induced pulmonary hypertension: Synergistic effects of sildenafil and erythropoietin in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012 Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Changing serum cytokines levels in patients with idiopathic pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Erythropoietin (EPO) inhibits the bleomycin (BLM)-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Pulmonary arterial hypertension in patients treated with interferon Source: Eur Respir J 2015; 46: 1851-1853 Year: 2015 Pulmonary arterial hypertension in patients treated with interferon Source: Eur Respir J 2014; 44: 1627-1634 Year: 2014 Pulmonary arterial hypertension in patients treated with interferon Source: Eur Respir J 2015; 46: 1849-1851 Year: 2015 The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia Source: International Congress 2017 – PAH and CTEPH Year: 2017 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015